A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

Prior treatment

• Has drug-induced SLE.
• History of prior CAR-T therapy.
• Receipt of a live/live-attenuated vaccine other than BCG within 8 weeks

Other illness

• History of antiphospholipid syndrome with thromboembolic event within 12 months
• History or current diagnosis of any disease, condition or treatment that may confound clinical assessments in the study.
• History of bone marrow/hematopoietic stem cell or solid organ transplant or planned receipt during the study period.
• Recent serious or ongoing infection, or risk for serious infection, or acute or chronic infection
• History within the past year or current clinically significant central nervous system disease, including but not limited to cerebrovascular accident, seizures, severe brain injury, dementia, Parkinson's disease, cerebellar disease, or multiple sclerosis
• Impaired cardiac function or clinically significant cardiac disease
• End stage renal disease or severe liver disease

Other

• Any acute, severe lupus related flare that needs immediate treatment
• Breastfeeding/lactating or pregnant women or women who intend to become pregnant at any time during the study.

• Age 16-70 years at the time of signing the informed consent
• Have a diagnosis of SLE by EULAR/ACR 2019 criteria for ≥6 months.
• Have at least one of an antinuclear antibody, anti-double-stranded deoxyribonucleic acid (dsDNA), or elevated anti-Smith (Sm) antibody
• Inadequate response to 2 prior standard of care therapies, used for at least three months
• SLE Disease Activity Index 2000 (SLEDAI-2K) score of ≥7 at Screening
• For LN cohort participants. Kidney biopsy result within 6 months prior to Screening indicating Class III or IV (alone or in combination with Class V).